RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION AND DIABETES
Recommended Citation
Rangavajla G, Ayub MT, Thoma F, Mulukutla S, Zhu J, Jain SK, Saba SF, Bhonsale A. RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION AND DIABETES. J Am Coll Cardiol 2024; 83(13):192.
Document Type
Conference Proceeding
Publication Date
4-1-2024
Publication Title
J Am Coll Cardiol
Abstract
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve glycemic, obesity, and cardiovascular outcomes in patients with diabetes mellitus (DM). Atrial fibrillation (AF) often coexists with DM, but large-scale real-world data on clinical outcomes with GLP-1 RA in AF patients with DM is limited. Methods We extracted clinical data from adult AF patients with DM and no heart failure (HF) from a large tertiary-care system. GLP-1 RA recipients were matched with non-GLP-1 RA controls using propensity score matching with 22 variables (fig. 1A) and caliper size 0.2. Baseline characteristics after matching were assessed with t tests. Differences between GLP-1 RA recipients and controls were evaluated via Kaplan-Meier analyses for all-cause mortality, MACE (death, myocardial infarction, stroke, or major bleed), and AF hospitalization. Results Of 24862 patients meeting inclusion criteria, 1261 GLP-1 RA recipients and 1261 controls were matched. Of the matching variables, only BMI showed a small but significant difference between groups (fig. 1A). Over a median follow up of 2.3 years (IQR 0.7-3.4), GLP-1 RA use was associated with significantly improved mortality and MACE, but not associated with AF hospitalization (fig. 1B). Conclusion In this large contemporary cohort of patients with AF and diabetes without HF, GLP-1 RA use was associated with improved hard clinical outcomes. While these results should be validated prospectively, they suggest a benefit from GLP-1 RA in this population. [Formula presented]
Volume
83
Issue
13
First Page
192
